Carto 3
Payments companies reported to CMS as associated with Carto 3. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Carto 3, per program year, as reported to CMS.
Who makes it
- Biosense Webster, INC. $9.2M associated with Carto 3 (2023-2025)
- Medical Device Business Services, INC. $5.7M associated with Carto 3 (2023-2025)
- Johnson and Johnson International $4,973 associated with Carto 3 (2023-2025)
- Shockwave Medical, INC $234 associated with Carto 3 (2023-2025)
- Depuy Synthes Sales INC. $44.80 associated with Carto 3 (2023-2025)
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Carto 3
These are the largest totals companies reported as associated with Carto 3. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Samuel Asirvatham | Rochester, MN | Clinical Cardiac Electrophysiology | $372,810.10 |
| Luigi Di Biase | Bronx, NY | Cardiovascular Disease | $363,785.20 |
| Warren Jackman | Oklahoma City, OK | Clinical Cardiac Electrophysiology | $300,769.64 |
| Joshua Silverstein | Pittsburgh, PA | Clinical Cardiac Electrophysiology | $241,279.07 |
| Jason Zagrodzky | Austin, TX | Clinical Cardiac Electrophysiology | $241,088.16 |
| Brett Gidney | Santa Barbara, CA | Clinical Cardiac Electrophysiology | $229,868.41 |
| Christopher Porterfield | Aurora, CO | Clinical Cardiac Electrophysiology | $210,235.18 |
| Jonathan Dukes | Ventura, CA | Clinical Cardiac Electrophysiology | $204,741.47 |
| Fermin Garcia | Philadelphia, PA | Clinical Cardiac Electrophysiology | $193,961.17 |
| Shephal Doshi | Santa Monica, CA | Clinical Cardiac Electrophysiology | $188,939.64 |
Prescribed Carto 3?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.